RESUMEN
Objective:To evaluate the in vitro cross-neutralization of serum antibodies in human and mice immunized with inactivated SARS-CoV-2 vaccine against Delta and Beta variants. Methods:Human serum samples after a second and a third dose of inactivated SARS-CoV-2 vaccine and mouse serum samples after a two-dose vaccination were collected. The neutralizing antibodies in the samples against SARS-CoV-2 strains of prototype, Delta and Beta variants were detected using micro-neutralization assay in biosafety level Ⅲ laboratory. The seroconversion rates and geometric mean titers (GMTs) of antibodies were calculated.Results:The seroconversion rates of antibodies in human serum samples against different SARS-CoV-2 strains were all above 95%. After two-dose vaccination, the GMTs of neutralizing antibodies against the prototype, Delta and Beta strains were 109, 41 and 15, respectively. The GMTs decreased by 2.7 folds and 7.3 folds for the Delta and Beta variants as compared with the prototype strain. After the booster vaccination, the GMTs of neutralizing antibodies against the prototype, Delta and Beta strains were 446, 190 and 86, respectively. The GMTs of neutralizing antibodies against Delta and Beta variants decreased by 2.3 folds and 5.2 folds as compared with that against the prototype strain. The seroconversion rates of antibodies against different SARS-CoV-2 strains in mouse serum samples were all 100%. The GMTs of neutralizing antibodies against the prototype, Delta and Beta strains were 2 037, 862 and 408, respectively. The GMTs decreased by 2.4 folds and 5.0 folds for the Delta and Beta variants.Conclusions:Inactivated SARS-CoV-2 vaccine could induce a certain level of neutralizing antibodies against Delta and Beta variants in both human and mouse models. Moreover, a third dose of vaccine induced higher levels of neutralizing antibodies against Delta and Beta variants in human. This study provided valuable data for the clinical application and protective evaluation of the inactivated SARS-CoV-2 vaccine.
RESUMEN
Guanxin Tongluo capsule is a compound traditional Chinese medicine preparation for the treatment of coronary heart disease. The underlying mechanism may be related to expanding coronary artery, increasing coronary artery blood flow, reducing myocardial oxygen consumption, and decreasing whole blood viscosity, plasma viscosity, and hematocrit. This paper reviews the clinical research progress of Guanxin Tongluo capsule in the treatment of coronary heart disease from the aspects of etiology, pathogenesis, pharmacological research, and clinical research, providing evidence for scientific research and clinical application of Guanxin Tongluo capsule.
RESUMEN
Objective To observe the clinical efficacy of Huxinkang Pills in treating patients with unstable angina pectoris (UAP) and its effects on the tumor necrosis factor-α (TNF-α) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Methods Sixty patients with UAP were randomly divided into the treatment group and the control group, 30 cases in each group. Patients in the treatment group were treated with Huxinkang Pills based on the basic western medicine, while the patients in the control group were treated with Tongxinluo Capsules based on the basic western medicine. The treatment course was 4 weeks. Clinical efficacy and the change of the TNF-α and NT-proBNP levels before and after treatment were observed. Results The general efficacy, electrocardiograph efficacy, angina pectoris efficacy, TCM syndrome efficacy and glonoine reduction of the two groups had statistically difference (P<0.05) respectively, and the efficacy of the treatment group was superior to that of the control group (P<0.05). The TNF-α and NT-proBNP levels in both groups before and after treatment had statistically difference (P<0.05) respectively. The differences in TNF-α and NT-proBNP levels between both groups after treatment were all statistically significant (P<0.05), and these indexes of treatment group were superior to those of the control group (P<0.05). Conclusion Huxinkang Pills are remarkable in treating patients with UAP, and able to restrain the levels of TNF-α and NT-proBNP.
RESUMEN
Half of the heart failure patients are the diastolic heart failure (DHF) patients, and the occurrence of DHF increases as the patients’ age increases, which has seriously affected the quality of life of the elderly. However, there is presently no valid medication of DHF, thus the treatment of DHF is one of the hotspot of the medicine research. This article reviewsed the TCM in the cognition and treatment of DHF these years, in order to provide references for TCM in treating DHF.
RESUMEN
BACKGROUND:Hyperbaric oxygen therapy can improve the microenvironment of the injured spinal cord, and hyperbaric oxygen combined with Schwann cel transplantation is expected to improve the therapeutic efficacy on spinal cord injury. OBJECTIVE:To investigate the effect of Schwann cel transplantation plus hyperbaric oxygen on the neural functional recovery of rats with spinal cord injury. METHODS:A total of 80 female SD rats with spinal cord injury were randomized into 4 groups, with 20 in each group:blank control group, injection of L-DMEM via the tail vein at 6 hours after modeling;cel transplantation group, injection of 3×106 RESULTS AND CONCLUSION:The motor function of the lower limbs was better in the combination group than the cel transplantation and hyperbaric oxygen groups, as wel as better in the cel transplantation group and Schwann cel suspension via the tail vein at 6 hours after modeling;hyperbaric oxygen group, hyperbaric oxygen therapy at 1 hour after modeling;combination group, combined therapy of Schwann cel transplantation and hyperbaric oxygen. Inclined plane test, modified Tarlov score, Basso-Beattie-Bresnahan score for motor function evaluation of rat hind limbs were performed and measured at 1, 3 days, 1, 2, 3, 4 weeks after treatment. SRY gene expression in the spinal cord was measured at 4 weeks after transplantation using PCR method. Horseradish peroxidase tracer and electroneurophysiology detection was done at 8 weeks after transplantation.hyperbaric oxygen groups than the blank control group. SRY expression was detected in the cel transplantation group and combination group, but not in the blank control group and hyperbaric oxygen group. The number of nerve fibers positive for horseradish peroxidase was higher in the combination group than the cel transplantation and hyperbaric oxygen groups fol owed by the blank control group, and there were significant differences between different groups (P<0.01). In addition, the latencies and amplitudes of somatosensory evoked potential and motor evoked potential in the combination group were also better than those in the other groups (P<0.05 or P<0.01). These findings indicate that the combined therapy of Schwann cel transplantation and hyperbaric oxygen can promote the synaptic regeneration, improve limb motor function and electrophysiological function in rats with spinal cord injury, which is superior to hyperbaric oxygen or Schwann cel transplantation alone.